Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects

ALK-Abelló A/S800 enrolled

Overview

The purpose of the trial is to determine if treatment of asthma patients allergic to house dust mites with the ALK HDM tablet can reduce the need of inhaled corticosteroids (ICS).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

800

Conditions

Asthma

Interventions

ALK HDM tabletDRUG

Eligibility

Sex: ALLMin age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A history of house dust mite induced asthma * Use of inhaled corticosteroids (ICS) * Positive skin prick test to house dust mites * Positive specific IgE to house dust mites Exclusion Criteria: * FEV1 lower than 70%

Locations (1)

Rigshospitalet

Copenhagen, Copenhagen, Denmark

Outcomes

Primary Outcomes

Use of inhaled corticosteroid (ICS).

Secondary Outcomes

Use of rescue medication and symptoms.

Quality of Life.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.